Information Provided By:
Fly News Breaks for January 31, 2020
Jan 31, 2020 | 07:11 EDT
SunTrust analyst Robyn Karnauskas raised her price target on Alexion to $141 and kept her Buy rating after its Q4 earnings beat, adding that the company's below-consensus FY20 guidance is "conservative". The analyst cites her "extensive" discussion with the management on pricing and notes that if Alexion can top its guidance of U.S. neurology patient treatments, that would add over $20 per share in her valuation model.
News For ALXN From the Last 2 Days
There are no results for your query ALXN